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OBJECTIVE: The purpose of this study was to examine the association of anemia, iron deficiency, and related hematological parameters with early (defined as
the period of 90 days post-discharge) rehospitalization due to HF and all-cause mortality, and long-term all-cause mortality in HF patients.
BACKGROUND: In patients with heart failure (HF), anemia and iron deficiency are predictors of poor long-term outcome.
PARTNERSHIPS 
 
 
 
 
 
 
 
 
 
 
 
N=65 HF patients
Mean age: 79.2 (SD 10.8)
Median follow-up : 13.7 months
[Q1: 6.7 to Q3: 18.9]
RESULTS
Characteristics Patients (n=65)
Age, mean (SD) 79.2 ± 10.8
Female Gender, n (%) 37 (56.9)
Hypertension, n (%) 58 (89.2)
Type 2 Diabetes, n (%) 25 (38.5)
Dyslipidemia, n (%) 41 (63.1)
Obesity, n (%) 17 (26.2)
Atrial Fibrillation, n (%) 28 (43.1)
Family History of CVD, n (%) 31 (47.7)
Tabagism, n (%) 21 (32.3)
Chronic Kidney Disease, n (%) 34 (52.3)
GFR (Baseline), median 57.8 (43.8 - 82.2)
GFR (Admission), median 47.9 (33.2 - 68.1)
Previous Acute Myocardial Infarction, n (%) 27 (41.5)
Hypertensive Cardiomyopathy, n (%) 44 (67.7)
Ischemic Cardiomyopathy, n (%) 22 (33.8)
Valvular Cardiomyopathy, n (%) 56 (86.2)
LVEF, mean (SD) 50.38 ± 19.07
NYHA class III, n (%) 43 (66.2)
ACE Inhibitor, n (%) 43 (66.2)
Beta Blocker, n (%) 38 (58.5)
Mineralocorticoid Receptor Antagonists, n (%) 19 (29.2)
Angiotensin II Receptor Blocker, n (%) 11 (16.9)
Loop Diuretic, n (%) 54 (83.1)
Digoxin, n (%) 8 (12.3)
Values are median (IQR), n (%), or mean±SD. 
IQR: interquartile range and 
minimum/maximum, SD: standard deviation, 
CVD: cardiovascular disease, GFR: glomerular 
filtration rate, ACE: Angiotensin-Converting-
Enzyme.
METHODS: Anemia, iron deficiency, red cell distribution width (RDW) and erythropoietin (EPO) were assessed in patients hospitalized with acute decompensated heart failure in
class III or IV of New York Heart Association (NYHA) to an Internal Medicine ward. Comparison between patients with and without each of the events was performed for all
variables using t test or Wilcoxon Rank test as applicable. Categorical variables were summarized by relative and absolute frequencies, and compared using chi-squared test or
Fisher’s Exact test as applicable. Univariate Cox proportional hazard model was used to assess the relationship between variables and outcomes.
CONCLUSION:
- Anemia, iron deficiency, RDW and EPO were associated with early rehospitalization, early mortality, and long-term mortality.
- Our findings may provide insight into HF prognosis and may raise the interest in some neglected hematological parameters.
- The recognition and treatment of risk factors that influence HF outcome, beyond HF specific therapy, may further contribute to ameliorate HF prognosis.
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[HR: 1.35, 95% CI: 1.16-1.5, P<0.05]
Anemia
Figure 4 - Baseline comparison of subjects by long-term 
mortality status: EPO
Characteristics Patients (n=65)
Hemoglobin, mean (SD) 11.7 ± 1.9
Red Blood Cell Distribution Width, median 15.0 (13.8 - 16.2)
Transferrin Saturation, median 14.0 (10 - 21)
Total Iron-Binding Capacity, mean (SD) 281.5 ± 76.1
Serum Iron, median 40.1 (27.6 - 60.1) 
Serum Ferritin, median 149.1 (52.3 - 350.9) 
Iron Deficiency, n (%) 30 (46.2) 
Anemia, n (%) 38 (58.5) 
Anemia with Iron Deficiency, n (%) 17 (26.2)
Absolute Iron Deficiency, n (%) 20 (30.1)
Functional Iron Deficiency, n (%) 10 (15.4)
Anemia without Iron Deficiency, n (%) 15 (23.0)
Iron Deficiency without Anemia, n (%) 13 (20.0)
Absolute Iron Deficiency without Anemia, n (%) 6 (9.2)
Functional Iron Deficiency without Anemia, n (%) 7 (10.8)
Table 1 – General baseline characteristics Table 2 – Hematological parameters baseline characteristics
Risk for early rehospitalization
Anemia with 
iron deficiency
[HR 3.81; 95% CI 1.29-11.28, P<0.05] [HR 3.50; 95% CI 1.30-9.38, P<0.05]
 
p-value: 0.012 * 
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Figure 1- Baseline comparison of subjects by early 
rehospitalization status: Anemia
 
p-value: 0.009 ** 
12 
16 
20 
24 
No Yes 
Early Rehospitalization 
Re
d 
Bl
oo
d 
Ce
ll 
Di
st
ri
bu
tio
n 
W
id
th
 (R
DW
) (
%
) 
 
p-value: 0.002 ** 
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Values are median (IQR), n (%), or mean±SD. 
IQR: interquartile range and 
minimum/maximum, SD: standard deviation.
Figure  2 - Baseline comparison of subjects by early 
rehospitalization status: RDW
Increased risk for early mortality
Characteristic
RDW
EPO
Absolute Iron Deficiency
Anemia with iron deficiency
HR 95% CI P value
1.83 1.29-2.59 <0.05
1.38 1.04-1.82 <0.05
7.22 1.50-34.81 <0.05
4.48 1.26-15.88 <0.05
20 1 43
Forest Plot of Hazard Ratios by Patient Subgroups
HR, Hazard ratio.
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Figure 3 - Short-term mortality - Kaplan Meier: Serum ferritin <100 ng/mL
Increased risk for long-term mortality
Characteristic
RDW
EPO
HR 95% CI P value
1.31 1.12-1.54 <0.05
1.29 1.11-1.9 <0.05
20 1 3
Forest Plot of Hazard Ratios by Patient Subgroups
HR, Hazard ratio.
